ID   MTOR_HUMAN              Reviewed;        2549 AA.
AC   P42345; Q4LE76; Q5TER1; Q6LE87; Q96QG3; Q9Y4I3;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   22-JUL-2015, entry version 164.
DE   RecName: Full=Serine/threonine-protein kinase mTOR;
DE            EC=2.7.11.1;
DE   AltName: Full=FK506-binding protein 12-rapamycin complex-associated protein 1;
DE   AltName: Full=FKBP12-rapamycin complex-associated protein;
DE   AltName: Full=Mammalian target of rapamycin;
DE            Short=mTOR;
DE   AltName: Full=Mechanistic target of rapamycin;
DE   AltName: Full=Rapamycin and FKBP12 target 1;
DE   AltName: Full=Rapamycin target protein 1;
GN   Name=MTOR; Synonyms=FRAP, FRAP1, FRAP2, RAFT1, RAPT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=8008069; DOI=10.1038/369756a0;
RA   Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T.,
RA   Lane W.S., Schreiber S.L.;
RT   "A mammalian protein targeted by G1-arresting rapamycin-receptor
RT   complex.";
RL   Nature 369:756-758(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9653645; DOI=10.1006/geno.1997.5186;
RA   Onyango P., Lubyova B., Gardellin P., Kurzbauer R., Weith A.;
RT   "Molecular cloning and expression analysis of five novel genes in
RT   chromosome 1p36.";
RL   Genomics 50:187-198(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M.,
RA   Ohara R., Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long
RT   cDNAs encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1362-2549.
RX   PubMed=11426320; DOI=10.1038/sj.gene.6363745;
RA   Stover C., Endo Y., Takahashi M., Lynch N., Constantinescu C.,
RA   Vorup-Jensen T., Thiel S., Friedl H., Hankeln T., Hall R., Gregory S.,
RA   Fujita T., Schwaeble W.;
RT   "The human gene for mannan-binding lectin-associated serine protease-2
RT   (MASP-2), the effector component of the lectin route of complement
RT   activation, is part of a tightly linked gene cluster on chromosome
RT   1p36.2-3.";
RL   Genes Immun. 2:119-127(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1987-2146, AND TISSUE SPECIFICITY.
RC   TISSUE=B-cell;
RX   PubMed=7809080; DOI=10.1073/pnas.91.26.12574;
RA   Chiu M.I., Katz H., Berlin V.;
RT   "RAPT1, a mammalian homolog of yeast Tor, interacts with the
RT   FKBP12/rapamycin complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:12574-12578(1994).
RN   [8]
RP   SUBCELLULAR LOCATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=9434772; DOI=10.1006/bbrc.1997.7878;
RA   Withers D.J., Ouwens D.M., Nave B.T., van der Zon G.C.M.,
RA   Alarcon C.M., Cardenas M.E., Heitman J., Maassen J.A., Shepherd P.R.;
RT   "Expression, enzyme activity, and subcellular localization of
RT   mammalian target of rapamycin in insulin-responsive cells.";
RL   Biochem. Biophys. Res. Commun. 241:704-709(1997).
RN   [9]
RP   INTERACTION WITH UBQLN1.
RX   PubMed=11853878; DOI=10.1016/S0167-4889(01)00164-1;
RA   Wu S., Mikhailov A., Kallo-Hosein H., Hara K., Yonezawa K., Avruch J.;
RT   "Characterization of ubiquilin 1, an mTOR-interacting protein.";
RL   Biochim. Biophys. Acta 1542:41-56(2002).
RN   [10]
RP   FUNCTION IN NUTRIENT-DEPENDENT CELL GROWTH, FUNCTION IN
RP   PHOSPHORYLATION OF RPS6KB1, AND INTERACTION WITH RPTOR.
RX   PubMed=12150925; DOI=10.1016/S0092-8674(02)00808-5;
RA   Kim D.-H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R.,
RA   Erdjument-Bromage H., Tempst P., Sabatini D.M.;
RT   "mTOR interacts with raptor to form a nutrient-sensitive complex that
RT   signals to the growth machinery.";
RL   Cell 110:163-175(2002).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH RPTOR.
RX   PubMed=12150926; DOI=10.1016/S0092-8674(02)00833-4;
RA   Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S.,
RA   Tokunaga C., Avruch J., Yonezawa K.;
RT   "Raptor, a binding partner of target of rapamycin (TOR), mediates TOR
RT   action.";
RL   Cell 110:177-189(2002).
RN   [12]
RP   INTERACTION WITH CLIP1, AND FUNCTION IN PHOSPHORYLATION OF CLIP1.
RX   PubMed=12231510; DOI=10.1093/embo-reports/kvf197;
RA   Choi J.H., Bertram P.G., Drenan R., Carvalho J., Zhou H.H.,
RA   Zheng X.F.;
RT   "The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170
RT   kinase.";
RL   EMBO Rep. 3:988-994(2002).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF RPS6KB2.
RX   PubMed=12087098; DOI=10.1074/jbc.M204080200;
RA   Park I.H., Bachmann R., Shirazi H., Chen J.;
RT   "Regulation of ribosomal S6 kinase 2 by mammalian target of
RT   rapamycin.";
RL   J. Biol. Chem. 277:31423-31429(2002).
RN   [14]
RP   INTERACTION WITH MLST8 AND RPTOR, IDENTIFICATION IN THE MTORC1
RP   COMPLEX, AND TISSUE SPECIFICITY.
RX   PubMed=12408816; DOI=10.1016/S1097-2765(02)00636-6;
RA   Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L.,
RA   Bonenfant D., Oppliger W., Jenoe P., Hall M.N.;
RT   "Two TOR complexes, only one of which is rapamycin sensitive, have
RT   distinct roles in cell growth control.";
RL   Mol. Cell 10:457-468(2002).
RN   [15]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11930000; DOI=10.1073/pnas.261702698;
RA   Desai B.N., Myers B.R., Schreiber S.L.;
RT   "FKBP12-rapamycin-associated protein associates with mitochondria and
RT   senses osmotic stress via mitochondrial dysfunction.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:4319-4324(2002).
RN   [16]
RP   ENZYME REGULATION, AND FUNCTION IN RESPONSE TO LOW CELLULAR ENERGY.
RX   PubMed=14651849; DOI=10.1016/S0092-8674(03)00929-2;
RA   Inoki K., Zhu T., Guan K.L.;
RT   "TSC2 mediates cellular energy response to control cell growth and
RT   survival.";
RL   Cell 115:577-590(2003).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH MLST8.
RX   PubMed=12718876; DOI=10.1016/S1097-2765(03)00114-X;
RA   Kim D.-H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V.P.,
RA   Erdjument-Bromage H., Tempst P., Sabatini D.M.;
RT   "GbetaL, a positive regulator of the rapamycin-sensitive pathway
RT   required for the nutrient-sensitive interaction between raptor and
RT   mTOR.";
RL   Mol. Cell 11:895-904(2003).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF PRKCA, FUNCTION IN REGULATION OF THE
RP   ACTIN CYTOSKELETON, IDENTIFICATION IN THE MTORC2 COMPLEX, AND
RP   INTERACTION WITH RICTOR.
RX   PubMed=15268862; DOI=10.1016/j.cub.2004.06.054;
RA   Sarbassov D.D., Ali S.M., Kim D.-H., Guertin D.A., Latek R.R.,
RA   Erdjument-Bromage H., Tempst P., Sabatini D.M.;
RT   "Rictor, a novel binding partner of mTOR, defines a rapamycin-
RT   insensitive and raptor-independent pathway that regulates the
RT   cytoskeleton.";
RL   Curr. Biol. 14:1296-1302(2004).
RN   [19]
RP   ENZYME REGULATION, AND FUNCTION IN RESPONSE TO HYPOXIA.
RX   PubMed=15545625; DOI=10.1101/gad.1256804;
RA   Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H.,
RA   Hafen E., Witters L.A., Ellisen L.W., Kaelin W.G. Jr.;
RT   "Regulation of mTOR function in response to hypoxia by REDD1 and the
RT   TSC1/TSC2 tumor suppressor complex.";
RL   Genes Dev. 18:2893-2904(2004).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=14578359; DOI=10.1074/jbc.M305912200;
RA   Drenan R.M., Liu X., Bertram P.G., Zheng X.F.S.;
RT   "FKBP12-rapamycin-associated protein or mammalian target of rapamycin
RT   (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi
RT   apparatus.";
RL   J. Biol. Chem. 279:772-778(2004).
RN   [21]
RP   FUNCTION IN REGULATION OF THE ACTIN CYTOSKELETON, FUNCTION IN
RP   PHOSPHORYLATION OF PXN, IDENTIFICATION IN THE MTORC2 COMPLEX,
RP   INTERACTION WITH RICTOR, AND AUTOPHOSPHORYLATION.
RX   PubMed=15467718; DOI=10.1038/ncb1183;
RA   Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A.,
RA   Hall M.N.;
RT   "Mammalian TOR complex 2 controls the actin cytoskeleton and is
RT   rapamycin insensitive.";
RL   Nat. Cell Biol. 6:1122-1128(2004).
RN   [22]
RP   PHOSPHORYLATION AT THR-2446 AND SER-2448.
RX   PubMed=15905173; DOI=10.1074/jbc.M504045200;
RA   Holz M.K., Blenis J.;
RT   "Identification of S6 kinase 1 as a novel mammalian target of
RT   rapamycin (mTOR)-phosphorylating kinase.";
RL   J. Biol. Chem. 280:26089-26093(2005).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF AKT1.
RX   PubMed=15718470; DOI=10.1126/science.1106148;
RA   Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.;
RT   "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR
RT   complex.";
RL   Science 307:1098-1101(2005).
RN   [24]
RP   IDENTIFICATION IN THE MTORC2 COMPLEX, AND INTERACTION WITH PRR5.
RX   PubMed=17599906; DOI=10.1074/jbc.M704343200;
RA   Woo S.-Y., Kim D.-H., Jun C.-B., Kim Y.-M., Haar E.V., Lee S.-I.,
RA   Hegg J.W., Bandhakavi S., Griffin T.J., Kim D.-H.;
RT   "PRR5, a novel component of mTOR complex 2, regulates platelet-derived
RT   growth factor receptor beta expression and signaling.";
RL   J. Biol. Chem. 282:25604-25612(2007).
RN   [25]
RP   INTERACTION WITH AKT1S1, AND ENZYME REGULATION.
RX   PubMed=17386266; DOI=10.1016/j.molcel.2007.03.003;
RA   Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A.,
RA   Spooner E., Carr S.A., Sabatini D.M.;
RT   "PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein
RT   kinase.";
RL   Mol. Cell 25:903-915(2007).
RN   [26]
RP   IDENTIFICATION IN THE MTORC1 AND MTORC2 COMPLEXES, AND FUNCTION IN
RP   PHOSPHORYLATION OF RPS6KB1 AND SGK1.
RX   PubMed=18925875; DOI=10.1042/BJ20081668;
RA   Garcia-Martinez J.M., Alessi D.R.;
RT   "mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation
RT   and activation of serum- and glucocorticoid-induced protein kinase 1
RT   (SGK1).";
RL   Biochem. J. 416:375-385(2008).
RN   [27]
RP   FUNCTION IN LIPID SYNTHESIS AND CELL GROWTH.
RX   PubMed=18762023; DOI=10.1016/j.cmet.2008.07.007;
RA   Porstmann T., Santos C.R., Griffiths B., Cully M., Wu M., Leevers S.,
RA   Griffiths J.R., Chung Y.L., Schulze A.;
RT   "SREBP activity is regulated by mTORC1 and contributes to Akt-
RT   dependent cell growth.";
RL   Cell Metab. 8:224-236(2008).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2478 AND SER-2481, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [30]
RP   FUNCTION, ENZYME REGULATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18497260; DOI=10.1126/science.1157535;
RA   Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C.,
RA   Bar-Peled L., Sabatini D.M.;
RT   "The Rag GTPases bind raptor and mediate amino acid signaling to
RT   mTORC1.";
RL   Science 320:1496-1501(2008).
RN   [31]
RP   INTERACTION WITH DEPTOR, AND ENZYME REGULATION.
RX   PubMed=19446321; DOI=10.1016/j.cell.2009.03.046;
RA   Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A.,
RA   Kuehl W.M., Gray N.S., Sabatini D.M.;
RT   "DEPTOR is an mTOR inhibitor frequently overexpressed in multiple
RT   myeloma cells and required for their survival.";
RL   Cell 137:873-886(2009).
RN   [32]
RP   PHOSPHORYLATION AT SER-1261.
RX   PubMed=19487463; DOI=10.1128/MCB.01665-08;
RA   Acosta-Jaquez H.A., Keller J.A., Foster K.G., Ekim B., Soliman G.A.,
RA   Feener E.P., Ballif B.A., Fingar D.C.;
RT   "Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling
RT   and cell growth.";
RL   Mol. Cell. Biol. 29:4308-4324(2009).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1218, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [35]
RP   PHOSPHORYLATION AT SER-2448.
RX   PubMed=19145465; DOI=10.1007/s00726-008-0230-7;
RA   Rosner M., Siegel N., Valli A., Fuchs C., Hengstschlager M.;
RT   "mTOR phosphorylated at S2448 binds to raptor and rictor.";
RL   Amino Acids 38:223-228(2010).
RN   [36]
RP   SUBCELLULAR LOCATION, AND ENZYME REGULATION.
RX   PubMed=20381137; DOI=10.1016/j.cell.2010.02.024;
RA   Sancak Y., Bar-Peled L., Zoncu R., Markhard A.L., Nada S.,
RA   Sabatini D.M.;
RT   "Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is
RT   necessary for its activation by amino acids.";
RL   Cell 141:290-303(2010).
RN   [37]
RP   FUNCTION IN PHOSPHORYLATION OF DAP, AND FUNCTION IN AUTOPHAGY.
RX   PubMed=20537536; DOI=10.1016/j.cub.2010.04.041;
RA   Koren I., Reem E., Kimchi A.;
RT   "DAP1, a novel substrate of mTOR, negatively regulates autophagy.";
RL   Curr. Biol. 20:1093-1098(2010).
RN   [38]
RP   INTERACTION WITH TTI1.
RX   PubMed=20810650; DOI=10.1101/gad.1934210;
RA   Hurov K.E., Cotta-Ramusino C., Elledge S.J.;
RT   "A genetic screen identifies the Triple T complex required for DNA
RT   damage signaling and ATM and ATR stability.";
RL   Genes Dev. 24:1939-1950(2010).
RN   [39]
RP   INTERACTION WITH TELO2.
RX   PubMed=20801936; DOI=10.1101/gad.1956410;
RA   Takai H., Xie Y., de Lange T., Pavletich N.P.;
RT   "Tel2 structure and function in the Hsp90-dependent maturation of mTOR
RT   and ATR complexes.";
RL   Genes Dev. 24:2019-2030(2010).
RN   [40]
RP   INTERACTION WITH TELO2 AND TTI1.
RX   PubMed=20427287; DOI=10.1074/jbc.M110.121699;
RA   Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K.,
RA   Iemura S., Natsume T., Mizushima N.;
RT   "Tti1 and Tel2 are critical factors in mammalian target of rapamycin
RT   complex assembly.";
RL   J. Biol. Chem. 285:20109-20116(2010).
RN   [41]
RP   FUNCTION IN REGULATION OF RNA POLYMERASE III TRANSCRIPTION, AND
RP   FUNCTION IN PHOSPHORYLATION OF MAF1.
RX   PubMed=20516213; DOI=10.1128/MCB.00319-10;
RA   Michels A.A., Robitaille A.M., Buczynski-Ruchonnet D., Hodroj W.,
RA   Reina J.H., Hall M.N., Hernandez N.;
RT   "mTORC1 directly phosphorylates and regulates human MAF1.";
RL   Mol. Cell. Biol. 30:3749-3757(2010).
RN   [42]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-567 AND THR-1162, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [44]
RP   PHOSPHORYLATION AT SER-2159; THR-2164 AND SER-2481, AND MUTAGENESIS OF
RP   SER-2159 AND THR-2164.
RX   PubMed=21576368; DOI=10.1128/MCB.05437-11;
RA   Ekim B., Magnuson B., Acosta-Jaquez H.A., Keller J.A., Feener E.P.,
RA   Fingar D.C.;
RT   "mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell
RT   growth, and cell cycle progression.";
RL   Mol. Cell. Biol. 31:2787-2801(2011).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [46]
RP   FUNCTION IN PHOSPHORYLATION OF GRB10, AND FUNCTION IN INSR-DEPENDENT
RP   SIGNALING.
RX   PubMed=21659604; DOI=10.1126/science.1199498;
RA   Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D.,
RA   Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A.,
RA   Sabatini D.M.;
RT   "The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-
RT   mediated inhibition of growth factor signaling.";
RL   Science 332:1317-1322(2011).
RN   [47]
RP   INTERACTION WITH HTR6.
RX   PubMed=23027611; DOI=10.1002/emmm.201201410;
RA   Meffre J., Chaumont-Dubel S., Mannoury la Cour C., Loiseau F.,
RA   Watson D.J., Dekeyne A., Seveno M., Rivet J.M., Gaven F., Deleris P.,
RA   Herve D., Fone K.C., Bockaert J., Millan M.J., Marin P.;
RT   "5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed
RT   cognition in schizophrenia.";
RL   EMBO Mol. Med. 4:1043-1056(2012).
RN   [48]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [49]
RP   PHOSPHORYLATION AT THR-2173, AND MUTAGENESIS OF THR-2173.
RX   PubMed=24247430; DOI=10.1083/jcb.201305103;
RA   Halova L., Du W., Kirkham S., Smith D.L., Petersen J.;
RT   "Phosphorylation of the TOR ATP binding domain by AGC kinase
RT   constitutes a novel mode of TOR inhibition.";
RL   J. Cell Biol. 203:595-604(2013).
RN   [50]
RP   INTERACTION WITH NBN.
RX   PubMed=23762398; DOI=10.1371/journal.pone.0065586;
RA   Wang J.Q., Chen J.H., Chen Y.C., Chen M.Y., Hsieh C.Y., Teng S.C.,
RA   Wu K.J.;
RT   "Interaction between NBS1 and the mTOR/Rictor/SIN1 complex through
RT   specific domains.";
RL   PLoS ONE 8:E65586-E65586(2013).
RN   [51]
RP   FUNCTION, PHOSPHORYLATION OF RPS6KB1, AND REGULATION OF PYRIMIDINE
RP   SYNTHESIS.
RX   PubMed=23429704; DOI=10.1126/science.1228771;
RA   Robitaille A.M., Christen S., Shimobayashi M., Cornu M., Fava L.L.,
RA   Moes S., Prescianotto-Baschong C., Sauer U., Jenoe P., Hall M.N.;
RT   "Quantitative phosphoproteomics reveal mTORC1 activates de novo
RT   pyrimidine synthesis.";
RL   Science 339:1320-1323(2013).
RN   [52]
RP   FUNCTION, PHOSPHORYLATION OF RPS6KB1, AND REGULATION OF PYRIMIDINE
RP   SYNTHESIS.
RX   PubMed=23429703; DOI=10.1126/science.1228792;
RA   Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D.;
RT   "Stimulation of de novo pyrimidine synthesis by growth signaling
RT   through mTOR and S6K1.";
RL   Science 339:1323-1328(2013).
RN   [53]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2448, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [54]
RP   ENZYME REGULATION.
RX   PubMed=25561175; DOI=10.1038/nature14107;
RA   Rebsamen M., Pochini L., Stasyk T., de Araujo M.E., Galluccio M.,
RA   Kandasamy R.K., Snijder B., Fauster A., Rudashevskaya E.L.,
RA   Bruckner M., Scorzoni S., Filipek P.A., Huber K.V., Bigenzahn J.W.,
RA   Heinz L.X., Kraft C., Bennett K.L., Indiveri C., Huber L.A.,
RA   Superti-Furga G.;
RT   "SLC38A9 is a component of the lysosomal amino acid sensing machinery
RT   that controls mTORC1.";
RL   Nature 519:477-481(2015).
RN   [55]
RP   ENZYME REGULATION.
RX   PubMed=25567906; DOI=10.1126/science.1257132;
RA   Wang S., Tsun Z.Y., Wolfson R.L., Shen K., Wyant G.A., Plovanich M.E.,
RA   Yuan E.D., Jones T.D., Chantranupong L., Comb W., Wang T.,
RA   Bar-Peled L., Zoncu R., Straub C., Kim C., Park J., Sabatini B.L.,
RA   Sabatini D.M.;
RT   "Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine
RT   sufficiency to mTORC1.";
RL   Science 347:188-194(2015).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH
RP   FKBP1A AND INHIBITOR RAPAMYCIN.
RX   PubMed=8662507; DOI=10.1126/science.273.5272.239;
RA   Choi J., Chen J., Schreiber S.L., Clardy J.;
RT   "Structure of the FKBP12-rapamycin complex interacting with the
RT   binding domain of human FRAP.";
RL   Science 273:239-242(1996).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2018-2112 IN COMPLEX WITH
RP   FKBP1A AND INHIBITOR RAPAMYCIN.
RX   PubMed=10089303; DOI=10.1107/S0907444998014747;
RA   Liang J., Choi J., Clardy J.;
RT   "Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2
RT   A resolution.";
RL   Acta Crystallogr. D 55:736-744(1999).
RN   [58]
RP   3D-STRUCTURE MODELING, HEAT-REPEATS, AND TPR-REPEATS.
RX   PubMed=20060908; DOI=10.1016/j.jsb.2010.01.002;
RA   Knutson B.A.;
RT   "Insights into the domain and repeat architecture of target of
RT   rapamycin.";
RL   J. Struct. Biol. 170:354-363(2010).
RN   [59]
RP   CRYO-ELECTRON MICROSCOPY (26 ANGSTROMS) OF MTORC1 COMPLEX, AND
RP   SUBUNIT.
RX   PubMed=20542007; DOI=10.1016/j.molcel.2010.05.017;
RA   Yip C.K., Murata K., Walz T., Sabatini D.M., Kang S.A.;
RT   "Structure of the human mTOR complex I and its implications for
RT   rapamycin inhibition.";
RL   Mol. Cell 38:768-774(2010).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 1376-2549 IN COMPLEX WITH
RP   MLST8, SUBUNIT, TPR-REPEATS, DOMAINS, AND MUTAGENESIS OF HIS-2340.
RX   PubMed=23636326; DOI=10.1038/nature12122;
RA   Yang H., Rudge D.G., Koos J.D., Vaidialingam B., Yang H.J.,
RA   Pavletich N.P.;
RT   "mTOR kinase structure, mechanism and regulation.";
RL   Nature 497:217-223(2013).
RN   [61]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-8; THR-135; VAL-1083; VAL-1134;
RP   PHE-1178; VAL-2011; TYR-2215 AND LEU-2476.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [62]
RP   VARIANTS PHE-2220 AND ALA-2406.
RX   PubMed=21248752; DOI=10.1038/nature09639;
RA   Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P.,
RA   Davies H., Jones D., Lin M.L., Teague J., Bignell G., Butler A.,
RA   Cho J., Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C.,
RA   Jia M., Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A.,
RA   Mudie L., Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S.,
RA   Kahnoski R.J., Anema J., Tuveson D.A., Perez-Mancera P.A.,
RA   Mustonen V., Fischer A., Adams D.J., Rust A., Chan-On W., Subimerb C.,
RA   Dykema K., Furge K., Campbell P.J., Teh B.T., Stratton M.R.,
RA   Futreal P.A.;
RT   "Exome sequencing identifies frequent mutation of the SWI/SNF complex
RT   gene PBRM1 in renal carcinoma.";
RL   Nature 469:539-542(2011).
CC   -!- FUNCTION: Serine/threonine protein kinase which is a central
CC       regulator of cellular metabolism, growth and survival in response
CC       to hormones, growth factors, nutrients, energy and stress signals.
CC       MTOR directly or indirectly regulates the phosphorylation of at
CC       least 800 proteins. Functions as part of 2 structurally and
CC       functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR
CC       complex 1 and 2). Activated mTORC1 up-regulates protein synthesis
CC       by phosphorylating key regulators of mRNA translation and ribosome
CC       synthesis. This includes phosphorylation of EIF4EBP1 and release
CC       of its inhibition toward the elongation initiation factor 4E
CC       (eiF4E). Moreover, phosphorylates and activates RPS6KB1 and
CC       RPS6KB2 that promote protein synthesis by modulating the activity
CC       of their downstream targets including ribosomal protein S6,
CC       eukaryotic translation initiation factor EIF4B, and the inhibitor
CC       of translation initiation PDCD4. Stimulates the pyrimidine
CC       biosynthesis pathway, both by acute regulation through RPS6KB1-
CC       mediated phosphorylation of the biosynthetic enzyme CAD, and
CC       delayed regulation, through transcriptional enhancement of the
CC       pentose phosphate pathway which produces 5-phosphoribosyl-1-
CC       pyrophosphate (PRPP), an allosteric activator of CAD at a later
CC       step in synthesis, this function is dependent on the mTORC1
CC       complex. Regulates ribosome synthesis by activating RNA polymerase
CC       III-dependent transcription through phosphorylation and inhibition
CC       of MAF1 an RNA polymerase III-repressor. In parallel to protein
CC       synthesis, also regulates lipid synthesis through SREBF1/SREBP1
CC       and LPIN1. To maintain energy homeostasis mTORC1 may also regulate
CC       mitochondrial biogenesis through regulation of PPARGC1A. mTORC1
CC       also negatively regulates autophagy through phosphorylation of
CC       ULK1. Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-
CC       758', disrupting the interaction with AMPK and preventing
CC       activation of ULK1. Also prevents autophagy through
CC       phosphorylation of the autophagy inhibitor DAP. mTORC1 exerts a
CC       feedback control on upstream growth factor signaling that includes
CC       phosphorylation and activation of GRB10 a INSR-dependent signaling
CC       suppressor. Among other potential targets mTORC1 may phosphorylate
CC       CLIP1 and regulate microtubules. As part of the mTORC2 complex
CC       MTOR may regulate other cellular processes including survival and
CC       organization of the cytoskeleton. Plays a critical role in the
CC       phosphorylation at 'Ser-473' of AKT1, a pro-survival effector of
CC       phosphoinositide 3-kinase, facilitating its activation by PDK1.
CC       mTORC2 may regulate the actin cytoskeleton, through
CC       phosphorylation of PRKCA, PXN and activation of the Rho-type
CC       guanine nucleotide exchange factors RHOA and RAC1A or RAC1B.
CC       mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422'.
CC       Regulates osteoclastogensis by adjusting the expression of CEBPB
CC       isoforms (By similarity). {ECO:0000250|UniProtKB:Q9JLN9,
CC       ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925,
CC       ECO:0000269|PubMed:12150926, ECO:0000269|PubMed:12231510,
CC       ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849,
CC       ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718,
CC       ECO:0000269|PubMed:15545625, ECO:0000269|PubMed:15718470,
CC       ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:18762023,
CC       ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213,
CC       ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21659604,
CC       ECO:0000269|PubMed:23429703, ECO:0000269|PubMed:23429704}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activation of mTORC1 by growth factors such as
CC       insulin involves AKT1-mediated phosphorylation of TSC1-TSC2, which
CC       leads to the activation of the RHEB GTPase a potent activator of
CC       the protein kinase activity of mTORC1. Insulin-stimulated and
CC       amino acid-dependent phosphorylation at Ser-1261 promotes
CC       autophosphorylation and the activation of mTORC1. Activation by
CC       amino acids requires relocalization of the mTORC1 complex to
CC       lysosomes that is mediated by the Ragulator complex, SLC38A9, and
CC       the Rag GTPases RRAGA, RRAGB, RRAGC and RRAGD (PubMed:18497260,
CC       PubMed:20381137, PubMed:25561175, PubMed:25567906). On the other
CC       hand, low cellular energy levels can inhibit mTORC1 through
CC       activation of PRKAA1 while hypoxia inhibits mTORC1 through a
CC       REDD1-dependent mechanism which may also require PRKAA1. The
CC       kinase activity of MTOR within the mTORC1 complex is positively
CC       regulated by MLST8 and negatively regulated by DEPTOR and AKT1S1.
CC       MTOR phosphorylates RPTOR which in turn inhibits mTORC1. MTOR is
CC       the target of the immunosuppressive and anti-cancer drug rapamycin
CC       which acts in complex with FKBP1A/FKBP12, and specifically
CC       inhibits its kinase activity. mTORC2 is also activated by growth
CC       factors, but seems to be nutrient-insensitive. It may be regulated
CC       by RHEB but in an indirect manner through the PI3K signaling
CC       pathway. {ECO:0000269|PubMed:14651849,
CC       ECO:0000269|PubMed:15545625, ECO:0000269|PubMed:17386266,
CC       ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:19446321,
CC       ECO:0000269|PubMed:20381137, ECO:0000269|PubMed:25561175,
CC       ECO:0000269|PubMed:25567906}.
CC   -!- SUBUNIT: Part of the mammalian target of rapamycin complex 1
CC       (mTORC1) which contains MTOR, MLST8, RPTOR, AKT1S1/PRAS40 and
CC       DEPTOR. The mTORC1 complex is a 1 Md obligate dimer of two
CC       stoichiometric heterotetramers with overall dimensions of 290 A x
CC       210 A x 135 A. It has a rhomboid shape and a central cavity, the
CC       dimeric interfaces are formed by interlocking interactions between
CC       the two MTOR and the two RPTOR subunits. the MLST8 subunits forms
CC       distal foot-like protuberances, and contacts only one MTOR within
CC       the complex, while the small PRAS40 localizes to the midsection of
CC       the central core, in close proximity to RPTOR. Part of the
CC       mammalian target of rapamycin COmplex 2 (mTORC2) which contains
CC       MTOR, MLST8, PRR5, RICTOR, MAPKAP1 and DEPTOR. Interacts with
CC       PPAPDC3 and PML. Interacts with PRR5 and RICTOR; the interaction
CC       is direct within the mTORC2 complex. Interacts with UBQLN1.
CC       Interacts with TTI1 and TELO2. Interacts with CLIP1;
CC       phosphorylates and regulates CLIP1. Interacts with NBN. Interacts
CC       with HTR6 (PubMed:23027611). {ECO:0000269|PubMed:10089303,
CC       ECO:0000269|PubMed:11853878, ECO:0000269|PubMed:12150925,
CC       ECO:0000269|PubMed:12150926, ECO:0000269|PubMed:12231510,
CC       ECO:0000269|PubMed:12408816, ECO:0000269|PubMed:12718876,
CC       ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718,
CC       ECO:0000269|PubMed:17386266, ECO:0000269|PubMed:17599906,
CC       ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:19446321,
CC       ECO:0000269|PubMed:20427287, ECO:0000269|PubMed:20542007,
CC       ECO:0000269|PubMed:20801936, ECO:0000269|PubMed:20810650,
CC       ECO:0000269|PubMed:23027611, ECO:0000269|PubMed:23636326,
CC       ECO:0000269|PubMed:23762398, ECO:0000269|PubMed:8662507}.
CC   -!- INTERACTION:
CC       P31749:AKT1; NbExp=2; IntAct=EBI-359260, EBI-296087;
CC       Q8TB45:DEPTOR; NbExp=5; IntAct=EBI-359260, EBI-2359040;
CC       Q13541:EIF4EBP1; NbExp=2; IntAct=EBI-359260, EBI-74090;
CC       P62942:FKBP1A; NbExp=2; IntAct=EBI-359260, EBI-1027571;
CC       Q9BVC4:MLST8; NbExp=4; IntAct=EBI-359260, EBI-1387471;
CC       Q8TCU6:PREX1; NbExp=11; IntAct=EBI-359260, EBI-1046542;
CC       P62820:RAB1A; NbExp=4; IntAct=EBI-359260, EBI-716845;
CC       Q6R327:RICTOR; NbExp=27; IntAct=EBI-359260, EBI-1387196;
CC       Q8N122:RPTOR; NbExp=32; IntAct=EBI-359260, EBI-1567928;
CC       Q96EB6:SIRT1; NbExp=2; IntAct=EBI-359260, EBI-1802965;
CC       Q8NHX9:TPCN2; NbExp=2; IntAct=EBI-359260, EBI-5239949;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Peripheral
CC       membrane protein; Cytoplasmic side. Golgi apparatus membrane;
CC       Peripheral membrane protein; Cytoplasmic side. Mitochondrion outer
CC       membrane; Peripheral membrane protein; Cytoplasmic side. Lysosome.
CC       Cytoplasm {ECO:0000250}. Nucleus, PML body {ECO:0000250}.
CC       Note=Shuttles between cytoplasm and nucleus. Accumulates in the
CC       nucleus in response to hypoxia (By similarity). Targeting to
CC       lysosomes depends on amino acid availability and RRAGA and RRAGB.
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in numerous tissues, with highest
CC       levels in testis. {ECO:0000269|PubMed:12408816,
CC       ECO:0000269|PubMed:7809080}.
CC   -!- DOMAIN: The kinase domain (PI3K/PI4K) is intrinsically active but
CC       has a highly restricted catalytic center.
CC       {ECO:0000269|PubMed:23636326}.
CC   -!- DOMAIN: The FAT domain forms three discontinuous subdomains of
CC       alpha-helical TPR repeats plus a single subdomain of HEAT repeats.
CC       The four domains pack sequentially to form a C-shaped a-solenoid
CC       that clamps onto the kinase domain (PubMed:23636326).
CC       {ECO:0000269|PubMed:23636326}.
CC   -!- PTM: Autophosphorylates when part of mTORC1 or mTORC2.
CC       Phosphorylation at Ser-1261, Ser-2159 and Thr-2164 promotes
CC       autophosphorylation. Phosphorylation in the kinase domain
CC       modulates the interactions of MTOR with RPTOR and PRAS40 and leads
CC       to increased intrinsic mTORC1 kinase activity. Phosphorylation at
CC       Thr-2173 in the ATP-binding region by AKT1 strongly reduces kinase
CC       activity. {ECO:0000269|PubMed:15905173,
CC       ECO:0000269|PubMed:18669648, ECO:0000269|PubMed:18691976,
CC       ECO:0000269|PubMed:19145465, ECO:0000269|PubMed:19369195,
CC       ECO:0000269|PubMed:19487463, ECO:0000269|PubMed:20068231,
CC       ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:23429703,
CC       ECO:0000269|PubMed:23429704, ECO:0000269|PubMed:24247430}.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 FAT domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00534}.
CC   -!- SIMILARITY: Contains 1 FATC domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00535}.
CC   -!- SIMILARITY: Contains 32 HEAT repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 PI3K/PI4K domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00269}.
CC   -!- SIMILARITY: Contains 16 TPR repeats. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC39933.1; Type=Frameshift; Positions=956, 999; Evidence={ECO:0000305};
CC       Sequence=BAE06077.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FRAP1ID40639ch1p36.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Mammalian target of rapamycin
CC       entry;
CC       URL="http://en.wikipedia.org/wiki/Mammalian_target_of_rapamycin";
CC   -!- WEB RESOURCE: Name=Target mTOR; Note=mTOR signaling pathway and
CC       mTOR inhibition resource;
CC       URL="http://www.targetmtor.com/index.jsp";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L34075; AAA58486.1; -; mRNA.
DR   EMBL; U88966; AAC39933.1; ALT_FRAME; mRNA.
DR   EMBL; AB209995; BAE06077.1; ALT_INIT; mRNA.
DR   EMBL; AL109811; CAI22105.1; -; Genomic_DNA.
DR   EMBL; AL049653; CAI22105.1; JOINED; Genomic_DNA.
DR   EMBL; AL391561; CAI22105.1; JOINED; Genomic_DNA.
DR   EMBL; AL391561; CAI17228.1; -; Genomic_DNA.
DR   EMBL; AL049653; CAI17228.1; JOINED; Genomic_DNA.
DR   EMBL; AL109811; CAI17228.1; JOINED; Genomic_DNA.
DR   EMBL; AL049653; CAI22145.1; -; Genomic_DNA.
DR   EMBL; AL109811; CAI22145.1; JOINED; Genomic_DNA.
DR   EMBL; AL391561; CAI22145.1; JOINED; Genomic_DNA.
DR   EMBL; BC117166; AAI17167.1; -; mRNA.
DR   EMBL; AJ300188; CAC15570.1; -; Genomic_DNA.
DR   EMBL; L35478; AAC41713.1; -; mRNA.
DR   CCDS; CCDS127.1; -.
DR   PIR; S45340; S45340.
DR   RefSeq; NP_004949.1; NM_004958.3.
DR   RefSeq; XP_005263495.1; XM_005263438.1.
DR   UniGene; Hs.338207; -.
DR   PDB; 1AUE; X-ray; 2.33 A; A/B=2015-2114.
DR   PDB; 1FAP; X-ray; 2.70 A; B=2018-2112.
DR   PDB; 1NSG; X-ray; 2.20 A; B=2019-2112.
DR   PDB; 2FAP; X-ray; 2.20 A; B=2019-2112.
DR   PDB; 2GAQ; NMR; -; A=2015-2114.
DR   PDB; 2NPU; NMR; -; A=2015-2114.
DR   PDB; 2RSE; NMR; -; B=2019-2112.
DR   PDB; 3FAP; X-ray; 1.85 A; B=2019-2112.
DR   PDB; 4DRH; X-ray; 2.30 A; B/E=2025-2114.
DR   PDB; 4DRI; X-ray; 1.45 A; B=2025-2114.
DR   PDB; 4DRJ; X-ray; 1.80 A; B=2025-2114.
DR   PDB; 4FAP; X-ray; 2.80 A; B=2019-2112.
DR   PDB; 4JSN; X-ray; 3.20 A; A/B=1376-2549.
DR   PDB; 4JSP; X-ray; 3.30 A; A/B=1376-2549.
DR   PDB; 4JSV; X-ray; 3.50 A; A/B=1376-2549.
DR   PDB; 4JSX; X-ray; 3.50 A; A/B=1376-2549.
DR   PDB; 4JT5; X-ray; 3.45 A; A/B=1376-2549.
DR   PDB; 4JT6; X-ray; 3.60 A; A/B=1376-2549.
DR   PDBsum; 1AUE; -.
DR   PDBsum; 1FAP; -.
DR   PDBsum; 1NSG; -.
DR   PDBsum; 2FAP; -.
DR   PDBsum; 2GAQ; -.
DR   PDBsum; 2NPU; -.
DR   PDBsum; 2RSE; -.
DR   PDBsum; 3FAP; -.
DR   PDBsum; 4DRH; -.
DR   PDBsum; 4DRI; -.
DR   PDBsum; 4DRJ; -.
DR   PDBsum; 4FAP; -.
DR   PDBsum; 4JSN; -.
DR   PDBsum; 4JSP; -.
DR   PDBsum; 4JSV; -.
DR   PDBsum; 4JSX; -.
DR   PDBsum; 4JT5; -.
DR   PDBsum; 4JT6; -.
DR   ProteinModelPortal; P42345; -.
DR   SMR; P42345; 2025-2114, 2517-2549.
DR   BioGrid; 108757; 124.
DR   DIP; DIP-790N; -.
DR   IntAct; P42345; 52.
DR   MINT; MINT-121301; -.
DR   STRING; 9606.ENSP00000354558; -.
DR   BindingDB; P42345; -.
DR   ChEMBL; CHEMBL2842; -.
DR   DrugBank; DB01590; Everolimus.
DR   DrugBank; DB00337; Pimecrolimus.
DR   DrugBank; DB00877; Sirolimus.
DR   DrugBank; DB06287; Temsirolimus.
DR   GuidetoPHARMACOLOGY; 2109; -.
DR   PhosphoSite; P42345; -.
DR   BioMuta; MTOR; -.
DR   DMDM; 1169735; -.
DR   MaxQB; P42345; -.
DR   PaxDb; P42345; -.
DR   PRIDE; P42345; -.
DR   Ensembl; ENST00000361445; ENSP00000354558; ENSG00000198793.
DR   GeneID; 2475; -.
DR   KEGG; hsa:2475; -.
DR   UCSC; uc001asd.3; human.
DR   CTD; 2475; -.
DR   GeneCards; GC01M011166; -.
DR   HGNC; HGNC:3942; MTOR.
DR   HPA; CAB005057; -.
DR   MIM; 601231; gene.
DR   neXtProt; NX_P42345; -.
DR   PharmGKB; PA28360; -.
DR   eggNOG; COG5032; -.
DR   GeneTree; ENSGT00800000124112; -.
DR   HOGENOM; HOG000163215; -.
DR   HOVERGEN; HBG005744; -.
DR   InParanoid; P42345; -.
DR   KO; K07203; -.
DR   OMA; PAMEPHI; -.
DR   PhylomeDB; P42345; -.
DR   TreeFam; TF105134; -.
DR   Reactome; REACT_19358; CD28 dependent PI3K/Akt signaling.
DR   Reactome; REACT_21285; Regulation of AMPK activity via LKB1.
DR   Reactome; REACT_21393; Regulation of Rheb GTPase activity by AMPK.
DR   Reactome; REACT_263991; VEGFR2 mediated vascular permeability.
DR   Reactome; REACT_264164; HSF1-dependent transactivation.
DR   Reactome; REACT_355377; TP53 Regulates Metabolic Genes.
DR   Reactome; REACT_355468; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; REACT_6754; S6K1-mediated signalling.
DR   Reactome; REACT_6836; Release of eIF4E.
DR   Reactome; REACT_6838; mTOR signalling.
DR   Reactome; REACT_75829; PIP3 activates AKT signaling.
DR   SignaLink; P42345; -.
DR   ChiTaRS; MTOR; human.
DR   EvolutionaryTrace; P42345; -.
DR   GeneWiki; Mammalian_target_of_rapamycin; -.
DR   GenomeRNAi; 2475; -.
DR   NextBio; 9805; -.
DR   PRO; PR:P42345; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; P42345; -.
DR   CleanEx; HS_FRAP1; -.
DR   ExpressionAtlas; P42345; baseline and differential.
DR   Genevisible; P42345; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0012505; C:endomembrane system; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; NAS:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:0031931; C:TORC1 complex; IDA:UniProtKB.
DR   GO; GO:0031932; C:TORC2 complex; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008144; F:drug binding; IEA:InterPro.
DR   GO; GO:0016301; F:kinase activity; TAS:UniProtKB.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IBA:GO_Central.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0043022; F:ribosome binding; IEA:Ensembl.
DR   GO; GO:0001030; F:RNA polymerase III type 1 promoter DNA binding; IDA:UniProtKB.
DR   GO; GO:0001031; F:RNA polymerase III type 2 promoter DNA binding; IDA:UniProtKB.
DR   GO; GO:0001032; F:RNA polymerase III type 3 promoter DNA binding; IDA:UniProtKB.
DR   GO; GO:0001156; F:TFIIIC-class transcription factor binding; IDA:UniProtKB.
DR   GO; GO:0006207; P:'de novo' pyrimidine nucleobase biosynthetic process; IEA:Ensembl.
DR   GO; GO:0055006; P:cardiac cell development; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:Reactome.
DR   GO; GO:0016049; P:cell growth; IDA:UniProtKB.
DR   GO; GO:0034605; P:cellular response to heat; TAS:Reactome.
DR   GO; GO:0071456; P:cellular response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0031669; P:cellular response to nutrient levels; ISS:UniProtKB.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; IBA:GO_Central.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0007281; P:germ cell development; IEA:Ensembl.
DR   GO; GO:0040007; P:growth; NAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0010507; P:negative regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:0045792; P:negative regulation of cell size; IEA:Ensembl.
DR   GO; GO:0016242; P:negative regulation of macroautophagy; IEA:Ensembl.
DR   GO; GO:1903147; P:negative regulation of mitochondrion degradation; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0051534; P:negative regulation of NFAT protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IEA:Ensembl.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0016310; P:phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; IEA:Ensembl.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0010592; P:positive regulation of lamellipodium assembly; IEA:Ensembl.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0010831; P:positive regulation of myotube differentiation; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl.
DR   GO; GO:0045945; P:positive regulation of transcription from RNA polymerase III promoter; IMP:UniProtKB.
DR   GO; GO:0045727; P:positive regulation of translation; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:MGI.
DR   GO; GO:0030163; P:protein catabolic process; TAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0043610; P:regulation of carbohydrate utilization; IEA:Ensembl.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:0031998; P:regulation of fatty acid beta-oxidation; IEA:Ensembl.
DR   GO; GO:0005979; P:regulation of glycogen biosynthetic process; IEA:Ensembl.
DR   GO; GO:0043087; P:regulation of GTPase activity; IEA:Ensembl.
DR   GO; GO:0031641; P:regulation of myelination; IEA:Ensembl.
DR   GO; GO:0045670; P:regulation of osteoclast differentiation; ISS:UniProtKB.
DR   GO; GO:0045859; P:regulation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:0032095; P:regulation of response to food; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IDA:UniProtKB.
DR   GO; GO:0007584; P:response to nutrient; NAS:UniProtKB.
DR   GO; GO:0006950; P:response to stress; IMP:UniProtKB.
DR   GO; GO:0031529; P:ruffle organization; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0031929; P:TOR signaling; IMP:UniProtKB.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 1.10.1070.11; -; 3.
DR   Gene3D; 1.20.120.150; -; 1.
DR   Gene3D; 1.25.10.10; -; 4.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR024585; DUF3385_TOR.
DR   InterPro; IPR003152; FATC.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR003151; PIK-rel_kinase_FAT.
DR   InterPro; IPR014009; PIK_FAT.
DR   InterPro; IPR009076; Rapamycin-bd_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom.
DR   Pfam; PF11865; DUF3385; 1.
DR   Pfam; PF02259; FAT; 1.
DR   Pfam; PF02260; FATC; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF08771; Rapamycin_bind; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF47212; SSF47212; 1.
DR   SUPFAM; SSF48371; SSF48371; 5.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51189; FAT; 1.
DR   PROSITE; PS51190; FATC; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome; Cytoplasm;
KW   Endoplasmic reticulum; Golgi apparatus; Kinase; Lysosome; Membrane;
KW   Mitochondrion; Mitochondrion outer membrane; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; TPR repeat; Transferase.
FT   CHAIN         1   2549       Serine/threonine-protein kinase mTOR.
FT                                /FTId=PRO_0000088808.
FT   REPEAT       16     53       HEAT 1.
FT   REPEAT       55     99       HEAT 2.
FT   REPEAT      100    137       HEAT 3.
FT   REPEAT      138    179       HEAT 4.
FT   REPEAT      180    220       HEAT 5.
FT   REPEAT      222    276       HEAT 6.
FT   REPEAT      277    313       HEAT 7.
FT   REPEAT      314    364       HEAT 8.
FT   REPEAT      365    409       HEAT 9.
FT   REPEAT      410    445       HEAT 10.
FT   REPEAT      446    494       HEAT 11.
FT   REPEAT      495    529       HEAT 12.
FT   REPEAT      530    563       HEAT 13.
FT   REPEAT      564    596       HEAT 14.
FT   REPEAT      597    636       HEAT 15.
FT   REPEAT      637    683       HEAT 16.
FT   REPEAT      686    724       HEAT 17.
FT   REPEAT      727    766       HEAT 18.
FT   REPEAT      769    811       HEAT 19.
FT   REPEAT      814    853       HEAT 20.
FT   REPEAT      857    893       HEAT 21.
FT   REPEAT      894    942       HEAT 22.
FT   REPEAT      943    988       HEAT 23.
FT   REPEAT      989   1027       HEAT 24.
FT   REPEAT     1029   1068       HEAT 25.
FT   REPEAT     1069   1105       HEAT 26.
FT   REPEAT     1106   1144       HEAT 27.
FT   REPEAT     1145   1188       HEAT 28.
FT   REPEAT     1189   1225       HEAT 29.
FT   REPEAT     1226   1273       HEAT 30.
FT   REPEAT     1274   1311       HEAT 31.
FT   REPEAT     1312   1345       HEAT 32.
FT   REPEAT     1346   1382       TPR 1.
FT   DOMAIN     1382   1982       FAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00534}.
FT   REPEAT     1383   1408       TPR 2.
FT   REPEAT     1409   1442       TPR 3.
FT   REPEAT     1443   1473       TPR 4.
FT   REPEAT     1474   1507       TPR 5.
FT   REPEAT     1508   1541       TPR 6.
FT   REPEAT     1542   1574       TPR 7.
FT   REPEAT     1575   1614       TPR 8.
FT   REPEAT     1615   1649       TPR 9.
FT   REPEAT     1650   1693       TPR 10.
FT   REPEAT     1694   1731       TPR 11.
FT   REPEAT     1732   1786       TPR 12.
FT   REPEAT     1787   1846       TPR 13.
FT   REPEAT     1898   1930       TPR 14.
FT   REPEAT     1931   1970       TPR 15.
FT   REPEAT     1971   2005       TPR 16.
FT   DOMAIN     2182   2516       PI3K/PI4K. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00269}.
FT   DOMAIN     2517   2549       FATC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00534, ECO:0000255|PROSITE-
FT                                ProRule:PRU00535}.
FT   REGION        1    651       Interaction with NBN.
FT   REGION     2012   2144       Sufficient for interaction with the
FT                                FKBP1A/rapamycin complex. {ECO:0000250}.
FT   REGION     2258   2296       Interaction with MLST8.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000269|PubMed:22814378}.
FT   MOD_RES     567    567       Phosphoserine.
FT                                {ECO:0000269|PubMed:18691976,
FT                                ECO:0000269|PubMed:19369195,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES    1162   1162       Phosphothreonine.
FT                                {ECO:0000269|PubMed:20068231}.
FT   MOD_RES    1218   1218       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES    1261   1261       Phosphoserine.
FT                                {ECO:0000269|PubMed:19487463}.
FT   MOD_RES    2159   2159       Phosphoserine.
FT                                {ECO:0000269|PubMed:21576368}.
FT   MOD_RES    2164   2164       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21576368}.
FT   MOD_RES    2173   2173       Phosphothreonine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:24247430}.
FT   MOD_RES    2446   2446       Phosphothreonine; by RPS6KB1.
FT                                {ECO:0000269|PubMed:15905173}.
FT   MOD_RES    2448   2448       Phosphoserine; by RPS6KB1.
FT                                {ECO:0000269|PubMed:15905173,
FT                                ECO:0000269|PubMed:19145465,
FT                                ECO:0000269|PubMed:24275569}.
FT   MOD_RES    2478   2478       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES    2481   2481       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:21576368}.
FT   VARIANT       8      8       A -> S (in a lung large cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041537.
FT   VARIANT     135    135       M -> T (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041538.
FT   VARIANT    1083   1083       M -> V (in dbSNP:rs56164650).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041539.
FT   VARIANT    1134   1134       A -> V (in dbSNP:rs28730685).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041540.
FT   VARIANT    1178   1178       S -> F (in dbSNP:rs55975118).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041541.
FT   VARIANT    2011   2011       M -> V (in an ovarian mucinous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041542.
FT   VARIANT    2215   2215       S -> Y (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041543.
FT   VARIANT    2220   2220       L -> F (found in a renal cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21248752}.
FT                                /FTId=VAR_064733.
FT   VARIANT    2406   2406       V -> A (found in a renal cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:21248752}.
FT                                /FTId=VAR_064734.
FT   VARIANT    2476   2476       P -> L (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041544.
FT   MUTAGEN    2159   2159       S->A: Reduces mTORC1-associated S-2481
FT                                autophosphorylation; when associated with
FT                                A-2164. {ECO:0000269|PubMed:21576368}.
FT   MUTAGEN    2159   2159       S->D: Stronger phosphorylation of
FT                                RPS6KB1; when associated with E-2164.
FT                                {ECO:0000269|PubMed:21576368}.
FT   MUTAGEN    2164   2164       T->A: Reduces mTORC1-associated S-2481
FT                                autophosphorylation; when associated with
FT                                A-2159. {ECO:0000269|PubMed:21576368}.
FT   MUTAGEN    2164   2164       T->E: Stronger phosphorylation of
FT                                RPS6KB1; when associated with D-2159.
FT                                {ECO:0000269|PubMed:21576368}.
FT   MUTAGEN    2173   2173       T->A: Increased mTOR kinase activity.
FT                                {ECO:0000269|PubMed:24247430}.
FT   MUTAGEN    2340   2340       H->A: Barely detectable kinase activity.
FT                                {ECO:0000269|PubMed:23636326}.
FT   CONFLICT    353    353       K -> N (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    359    359       S -> N (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    364    364       D -> N (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    390    390       M -> L (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    430    430       R -> L (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    455    457       VLD -> GVE (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    461    461       A -> G (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    482    484       VFT -> FFN (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    489    489       L -> V (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    513    513       L -> I (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    539    539       L -> V (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    553    553       R -> C (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   CONFLICT    857    857       P -> L (in Ref. 3; BAE06077).
FT                                {ECO:0000305}.
FT   CONFLICT   1075   1075       I -> S (in Ref. 2; AAC39933).
FT                                {ECO:0000305}.
FT   HELIX      1387   1406       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1410   1422       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1426   1439       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1446   1452       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1456   1469       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1474   1486       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1490   1498       {ECO:0000244|PDB:4JSN}.
FT   STRAND     1501   1503       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1506   1521       {ECO:0000244|PDB:4JSN}.
FT   TURN       1522   1524       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1526   1533       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1541   1553       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1557   1572       {ECO:0000244|PDB:4JSN}.
FT   TURN       1573   1577       {ECO:0000244|PDB:4JSN}.
FT   TURN       1584   1586       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1587   1605       {ECO:0000244|PDB:4JSN}.
FT   STRAND     1606   1608       {ECO:0000244|PDB:4JSP}.
FT   HELIX      1609   1611       {ECO:0000244|PDB:4JSX}.
FT   HELIX      1612   1624       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1630   1640       {ECO:0000244|PDB:4JSN}.
FT   TURN       1641   1643       {ECO:0000244|PDB:4JSN}.
FT   TURN       1646   1648       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1650   1663       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1666   1677       {ECO:0000244|PDB:4JSN}.
FT   STRAND     1681   1684       {ECO:0000244|PDB:4JSP}.
FT   HELIX      1694   1706       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1710   1729       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1737   1762       {ECO:0000244|PDB:4JSN}.
FT   TURN       1766   1768       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1769   1782       {ECO:0000244|PDB:4JSN}.
FT   TURN       1783   1785       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1787   1813       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1868   1893       {ECO:0000244|PDB:4JSN}.
FT   STRAND     1896   1898       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1900   1913       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1917   1929       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1933   1938       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1939   1943       {ECO:0000244|PDB:4JSN}.
FT   TURN       1944   1947       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1951   1966       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1970   1980       {ECO:0000244|PDB:4JSN}.
FT   HELIX      1985   2020       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2025   2039       {ECO:0000244|PDB:4DRI}.
FT   HELIX      2044   2058       {ECO:0000244|PDB:4DRI}.
FT   HELIX      2065   2091       {ECO:0000244|PDB:4DRI}.
FT   HELIX      2094   2111       {ECO:0000244|PDB:4DRI}.
FT   HELIX      2115   2117       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2119   2122       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2123   2126       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2128   2132       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2137   2139       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2152   2156       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2158   2162       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2165   2167       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2170   2176       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2181   2189       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2193   2211       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2213   2217       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2227   2229       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2231   2233       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2235   2238       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2243   2245       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2246   2256       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2263   2271       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2275   2277       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2280   2291       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2298   2306       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2310   2334       {ECO:0000244|PDB:4JSN}.
FT   TURN       2341   2343       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2344   2347       {ECO:0000244|PDB:4JSN}.
FT   TURN       2348   2350       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2353   2355       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2364   2367       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2369   2371       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2381   2386       {ECO:0000244|PDB:4JSN}.
FT   TURN       2389   2394       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2395   2409       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2411   2422       {ECO:0000244|PDB:4JSN}.
FT   TURN       2425   2427       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2428   2435       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2493   2507       {ECO:0000244|PDB:4JSN}.
FT   TURN       2508   2510       {ECO:0000244|PDB:4JSN}.
FT   STRAND     2512   2516       {ECO:0000244|PDB:4JT5}.
FT   HELIX      2521   2533       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2535   2538       {ECO:0000244|PDB:4JSN}.
FT   HELIX      2543   2545       {ECO:0000244|PDB:4JSN}.
SQ   SEQUENCE   2549 AA;  288892 MW;  7D9AD6E784882AB4 CRC64;
     MLGTGPAAAT TAATTSSNVS VLQQFASGLK SRNEETRAKA AKELQHYVTM ELREMSQEES
     TRFYDQLNHH IFELVSSSDA NERKGGILAI ASLIGVEGGN ATRIGRFANY LRNLLPSNDP
     VVMEMASKAI GRLAMAGDTF TAEYVEFEVK RALEWLGADR NEGRRHAAVL VLRELAISVP
     TFFFQQVQPF FDNIFVAVWD PKQAIREGAV AALRACLILT TQREPKEMQK PQWYRHTFEE
     AEKGFDETLA KEKGMNRDDR IHGALLILNE LVRISSMEGE RLREEMEEIT QQQLVHDKYC
     KDLMGFGTKP RHITPFTSFQ AVQPQQSNAL VGLLGYSSHQ GLMGFGTSPS PAKSTLVESR
     CCRDLMEEKF DQVCQWVLKC RNSKNSLIQM TILNLLPRLA AFRPSAFTDT QYLQDTMNHV
     LSCVKKEKER TAAFQALGLL SVAVRSEFKV YLPRVLDIIR AALPPKDFAH KRQKAMQVDA
     TVFTCISMLA RAMGPGIQQD IKELLEPMLA VGLSPALTAV LYDLSRQIPQ LKKDIQDGLL
     KMLSLVLMHK PLRHPGMPKG LAHQLASPGL TTLPEASDVG SITLALRTLG SFEFEGHSLT
     QFVRHCADHF LNSEHKEIRM EAARTCSRLL TPSIHLISGH AHVVSQTAVQ VVADVLSKLL
     VVGITDPDPD IRYCVLASLD ERFDAHLAQA ENLQALFVAL NDQVFEIREL AICTVGRLSS
     MNPAFVMPFL RKMLIQILTE LEHSGIGRIK EQSARMLGHL VSNAPRLIRP YMEPILKALI
     LKLKDPDPDP NPGVINNVLA TIGELAQVSG LEMRKWVDEL FIIIMDMLQD SSLLAKRQVA
     LWTLGQLVAS TGYVVEPYRK YPTLLEVLLN FLKTEQNQGT RREAIRVLGL LGALDPYKHK
     VNIGMIDQSR DASAVSLSES KSSQDSSDYS TSEMLVNMGN LPLDEFYPAV SMVALMRIFR
     DQSLSHHHTM VVQAITFIFK SLGLKCVQFL PQVMPTFLNV IRVCDGAIRE FLFQQLGMLV
     SFVKSHIRPY MDEIVTLMRE FWVMNTSIQS TIILLIEQIV VALGGEFKLY LPQLIPHMLR
     VFMHDNSPGR IVSIKLLAAI QLFGANLDDY LHLLLPPIVK LFDAPEAPLP SRKAALETVD
     RLTESLDFTD YASRIIHPIV RTLDQSPELR STAMDTLSSL VFQLGKKYQI FIPMVNKVLV
     RHRINHQRYD VLICRIVKGY TLADEEEDPL IYQHRMLRSG QGDALASGPV ETGPMKKLHV
     STINLQKAWG AARRVSKDDW LEWLRRLSLE LLKDSSSPSL RSCWALAQAY NPMARDLFNA
     AFVSCWSELN EDQQDELIRS IELALTSQDI AEVTQTLLNL AEFMEHSDKG PLPLRDDNGI
     VLLGERAAKC RAYAKALHYK ELEFQKGPTP AILESLISIN NKLQQPEAAA GVLEYAMKHF
     GELEIQATWY EKLHEWEDAL VAYDKKMDTN KDDPELMLGR MRCLEALGEW GQLHQQCCEK
     WTLVNDETQA KMARMAAAAA WGLGQWDSME EYTCMIPRDT HDGAFYRAVL ALHQDLFSLA
     QQCIDKARDL LDAELTAMAG ESYSRAYGAM VSCHMLSELE EVIQYKLVPE RREIIRQIWW
     ERLQGCQRIV EDWQKILMVR SLVVSPHEDM RTWLKYASLC GKSGRLALAH KTLVLLLGVD
     PSRQLDHPLP TVHPQVTYAY MKNMWKSARK IDAFQHMQHF VQTMQQQAQH AIATEDQQHK
     QELHKLMARC FLKLGEWQLN LQGINESTIP KVLQYYSAAT EHDRSWYKAW HAWAVMNFEA
     VLHYKHQNQA RDEKKKLRHA SGANITNATT AATTAATATT TASTEGSNSE SEAESTENSP
     TPSPLQKKVT EDLSKTLLMY TVPAVQGFFR SISLSRGNNL QDTLRVLTLW FDYGHWPDVN
     EALVEGVKAI QIDTWLQVIP QLIARIDTPR PLVGRLIHQL LTDIGRYHPQ ALIYPLTVAS
     KSTTTARHNA ANKILKNMCE HSNTLVQQAM MVSEELIRVA ILWHEMWHEG LEEASRLYFG
     ERNVKGMFEV LEPLHAMMER GPQTLKETSF NQAYGRDLME AQEWCRKYMK SGNVKDLTQA
     WDLYYHVFRR ISKQLPQLTS LELQYVSPKL LMCRDLELAV PGTYDPNQPI IRIQSIAPSL
     QVITSKQRPR KLTLMGSNGH EFVFLLKGHE DLRQDERVMQ LFGLVNTLLA NDPTSLRKNL
     SIQRYAVIPL STNSGLIGWV PHCDTLHALI RDYREKKKIL LNIEHRIMLR MAPDYDHLTL
     MQKVEVFEHA VNNTAGDDLA KLLWLKSPSS EVWFDRRTNY TRSLAVMSMV GYILGLGDRH
     PSNLMLDRLS GKILHIDFGD CFEVAMTREK FPEKIPFRLT RMLTNAMEVT GLDGNYRITC
     HTVMEVLREH KDSVMAVLEA FVYDPLLNWR LMDTNTKGNK RSRTRTDSYS AGQSVEILDG
     VELGEPAHKK TGTTVPESIH SFIGDGLVKP EALNKKAIQI INRVRDKLTG RDFSHDDTLD
     VPTQVELLIK QATSHENLCQ CYIGWCPFW
//
